Replies to post #347369 on Anavex Life Sciences Corp (AVXL)

[falconer66a]

Successful Anavex 3-71 Dosage Against Murine Alzheimer’s

In this study, of transgenic (Tg) rats with human Alzheimer’s genes (and disease), Anavex 3-71 (AF710B) was dosed at a rate of 10 µg/kg per day, orally administered. At that tiny dose Anavex 3-71 produced reversion of cognitive deficits of the disease --- a therapeutic success.

https://www.researchgate.net/publication/322142767_AF710B_an_M1sigma-1_receptor_agonist_with_long-lasting_disease-modifying_properties_in_a_transgenic_rat_model_of_Alzheimer's_disease

Here’s an excerpt:

Chronic treatment with AF710B [Anavex 3-71] (10 µg/kg) was initiated in postplaque 13-month-old Tg rats. Drug or vehicle was administered orally daily for 4.5 months and interrupted 5 weeks before behavioral testing. Results: AF710B long-term treatment reverted the cognitive deficits associated with advanced Alzheimer-like amyloid neuropathology in Tg rats.

One microgram (µg) is one millionth of a gram. At this dosage, a 150lb human (weighing 68 kg) with Alzheimer's would take 680 µg, 0.68 milligrams, each day. Less than a single milligram. By any measure, that’s very fractional compared to the many milligram doses of Anavex 2-73 (blarcamesine) being used in human clinical trials.

The research was reported in Alzheimer's & dementia: the journal of the Alzheimer's Association. It's "scientific."

[Investor2014]

I believe I compared the dose range results between the A3-71 and A2-73 P1 human trials.

But of course Anavex will ignore the 140mg broader dose range findings of A3-71 determined in a human P1 trial and eventually dose the next patients with up to 50,000 lower doses just to comply with an old preclinical paper based on murine results and two social media scientists.